RecruitingNCT07049653

Anifrolumab Pregnancy Study

A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data From Women With SLE Exposed to Anifrolumab

Sponsor

AstraZeneca

Enrollment

500 participants

Start Date

Jun 4, 2026

Study Type

OBSERVATIONAL

Conditions

Systemic Lupus Erythematosus

Summary

This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with systemic lupus erythematosus. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 130 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Research Site

Cary, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07049653

Related Trials

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

NCT054404221 location

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT0720155834 locations

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181138 locations

Study of Systemic Lupus Erythematosus

NCT000013721 location

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

NCT065940681 location